Concepedia

Publication | Open Access

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

DOIFull Paper Access

45

Citations

24

References

2014

Year

Ulrik Lassen, Didier Meulendijks, L.L. Siu, Vaios Karanikas, Morten Mau‐Sørensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary Ellen Simcox, Kathleen Schostack,
Clinical Cancer Research

Abstract

Fn14 signaling. Tumor regression was observed and prolonged stable disease was demonstrated in multiple heavily pretreated patients with solid tumors. These encouraging results support further study of RG7212. Clin Cancer Res; 21(2); 258-66. ©2014 AACR.

References

YearCitations

Page 1